Page 1

Q2-2021 Results HIGHLIGHTS Q2-2021 Sales increased by Ps . 229.1 million ; + 6.3 % year - on - year Ps . 70.5 million year - to - date interest expense decrease Cash & Equivalents closed at Ps . 1.41 billion as of June 30 , 2021 Q2-2021 Net Debt to EBITDA ratio closed at 1.59x 5,000,000 bottles of Suerox® produced in - house during June 2021 Capex Investments reached Ps . 318.4 million . in the six months ended June 30 , 2021 T Genomma Lab Internacional Reports Second Quarter 2021 Results 1 ) Mexico City , July 28 , 2021 Genomma Lab Internacional , S.A.B. de C.V. ( BMV : LAB B ) ( " Genomma Lab " or " the Company " ) , today announced its results for the second quarter ended June 30 , 2021. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards ( IFRS ) . The following tables provide an abridged Income Statement , in millions of Mexican pesos . The margin for each figure represents its ratio to net sales and the percentage change in the second quarter 2021 as compared with the same period in 2020 : Net Sales Gross Profit Operating Income EBITDA ( 1 ) Net Income Q2 2021 3,865.4 2,351.6 742.0 776.5 379.2 % Sales Comments from the CEO 100.0 % 60.8 % 19.2 % 20.1 % 9.8 % Genomma Lab Q2 2020 3,636.3 2,178.4 714.9 754.9 360.8 EBITDA defined as operating income before depreciation and amortization Internacional % Sales 100.0 % 59.9 % 19.7 % 20.8 % 9.9 % Var . % 6.3 % 8.0 % 3.8 % 2.9 % 5.1 % Mr. Jorge Luis Brake , Genomma Lab's Chief Executive Officer , commented : " We continued to deliver consistent growth during the first half of 2021 , following Genomma's strong 2020 results , despite the pandemic's ongoing economic and social impact . The second quarter of 2021 was one of the strongest quarters in Genomma's history , and the eleventh consecutive quarter of growth , driven by innovation and the continued implementation of our Four Pillar growth plan . This was characterized by line extensions , product repositioning and brand modernization through new and improved formulas and packaging , and supported by a business model which increases consumers ' access to our broad range of products at competitive price points . " He added : " Our strategy drives sustained profitable growth , as we continue to win with the consumer while strengthening efficiencies throughout every aspect of Genomma's business as part of our Continuous Improvement Program . Additionally , we remain focused on strengthening our ESG strategy ; delivering high - quality innovative products through sustainable initiatives while we nimbly adapt to evolving consumer demands . " www.genommalab.com/inversionistas/ 1